ABOUT THE PRODUCT
NeuroQuantix is a digitized spiral drawing assessment platform designed for clinical trial regulatory submission. It provides objective, quantitative motor endpoints across 23 neurological conditions, compliant with 21 CFR Part 11, EU GMP Annex 11, and GxP standards. The platform utilizes a deep kinematic library and iPad-based assessment for minimal site burden.
Information is owner-confirmed
Last updated 2 weeks ago
Price range
Other products/services from Cerebral Innovations
Clinical Trial Endpoints Consulting
Biotechnology
N/A
Cerebral Innovations
United States (US)